PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer

by Vandana Singh, Benzinga Editor

July 7, 2021 11:30 AM | 1 min read |

PureTech Health plc PRTC has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd BGNE.
The partnership will evaluate BeiGene's tislelizumab, in combination with PureTech's LYT-200 for the potential treatment of difficult-to-treat solid tumor indications.
LYT-200 is currently being evaluated as a single agent in the first phase of an adaptive Phase 1/2 clinical trial. PureTech expects to report topline Phase 1 results in Q4 of 2021.
Under the terms of the agreement, PureTech will maintain control of the LYT-200 program, including global R&D and commercial rights.
BeiGene has agreed to supply tislelizumab for use in combination with LYT-200.
Price Action: BGNE shares are down 1.68% at $318.20 on the last check Wednesday.

Posted In: Biotech News Health Care Contracts Small Cap General Briefs cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.